Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)

Q: What does CUSIP 761330109 represent in this 13F holders report?

CUSIP 761330109 is the security identifier for RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q4 2014?

68 institutional investors reported RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q4 2014. Use the holders table for investor-level position and value details.

CUSIP: 761330109

Q4 2014 13F Holders as of 31 Dec 2014

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 104,661,494
Total 13F shares: 19,758,262
Share change: +961,586
Total reported value: $334,697,612
Price per share: $16.94
Number of holders: 68
Value change: +$8,318,779
Number of buys: 38
Number of sells: 38

Quarterly Holders Quick Answers

What is CUSIP 761330109?
CUSIP 761330109 identifies RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2015
Previous quarter: Q3 2014

Recent filing periods for CUSIP 761330109:

Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024

Top shareholders of RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Essex Woodlands Management, Inc.	13F	Company	4.4%	4,592,047	$88,764,000	—	30 Sep 2014	13F
FRANKLIN RESOURCES INC	13F	Company	1.3%	1,386,899	$26,809,000	—	30 Sep 2014	13F
FMR LLC	13F	Company	0.98%	1,029,800	$19,906,000	—	30 Sep 2014	13F
JPMORGAN CHASE & CO	13F	Company	0.76%	790,817	$15,287,000	—	30 Sep 2014	13F
ArrowMark Colorado Holdings LLC	13F	Company	0.67%	702,550	$13,580,000	—	30 Sep 2014	13F
Polar Capital LLP	13F	Company	0.66%	689,780	$13,332,000	—	30 Sep 2014	13F
COLUMBIA WANGER ASSET MANAGEMENT LLC	13F	Company	0.54%	562,000	$10,863,000	—	30 Sep 2014	13F
ALLIANCEBERNSTEIN L.P.	13F	Company	0.49%	515,614	$9,967,000	—	30 Sep 2014	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.41%	425,445	$8,224,000	—	30 Sep 2014	13F
RS INVESTMENT MANAGEMENT CO LLC	13F	Company	0.4%	421,566	$8,149,000	—	30 Sep 2014	13F
PFM Health Sciences, LP	13F	Company	0.37%	388,467	$7,509,000	—	30 Sep 2014	13F
WADDELL & REED FINANCIAL INC	13F	Company	0.36%	376,150	$7,271,000	—	30 Sep 2014	13F
VANGUARD GROUP INC	13F	Company	0.3%	318,262	$6,152,000	—	30 Sep 2014	13F
JENNISON ASSOCIATES LLC	13F	Company	0.29%	299,194	$5,783,000	—	30 Sep 2014	13F
LORD, ABBETT & CO. LLC	13F	Company	0.27%	278,607	$5,385,000	—	30 Sep 2014	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.22%	234,492	$4,533,000	—	30 Sep 2014	13F
BlackRock Fund Advisors	13F	Company	0.19%	201,636	$3,898,000	—	30 Sep 2014	13F
Lombard Odier Asset Management (USA) Corp	13F	Company	0.19%	199,895	$3,864,000	—	30 Sep 2014	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.15%	153,984	$2,977,000	—	30 Sep 2014	13F
Adamant Biomedical Investments AG	13F	Company	0.12%	130,000	$2,513,000	—	30 Sep 2014	13F
Rhenman & Partners Asset Management AB	13F	Company	0.1%	105,255	$2,035,000	—	30 Sep 2014	13F
STATE STREET CORP	13F	Company	0.09%	98,859	$1,914,000	—	30 Sep 2014	13F
SABBY MANAGEMENT, LLC	13F	Company	0.09%	95,800	$1,852,000	—	30 Sep 2014	13F
BlackRock Institutional Trust Company, N.A.	13F	Company	0.09%	94,138	$1,820,000	—	30 Sep 2014	13F
Nicholas Investment Partners, LP	13F	Company	0.09%	92,288	$1,784,000	—	30 Sep 2014	13F
NORTHERN TRUST CORP	13F	Company	0.09%	90,979	$1,758,000	—	30 Sep 2014	13F
Zweig-DiMenna Associates LLC	13F	Company	0.08%	84,460	$1,633,000	—	30 Sep 2014	13F
Bank of New York Mellon Corp	13F	Company	0.08%	83,984	$1,623,000	—	30 Sep 2014	13F
LEVIN CAPITAL STRATEGIES, L.P.	13F	Company	0.08%	82,655	$1,598,000	—	30 Sep 2014	13F
Palo Alto Investors LP	13F	Company	0.08%	80,369	$1,554,000	—	30 Sep 2014	13F
DRIEHAUS CAPITAL MANAGEMENT LLC	13F	Company	0.07%	74,289	$1,436,000	—	30 Sep 2014	13F
HIGHLAND CAPITAL MANAGEMENT LP	13F	Company	0.07%	72,866	$1,408,000	—	30 Sep 2014	13F
PRINCIPAL FINANCIAL GROUP INC	13F	Company	0.07%	72,616	$1,404,000	—	30 Sep 2014	13F
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	13F	Company	0.06%	65,200	$1,260,000	—	30 Sep 2014	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.06%	63,131	$1,220,000	—	30 Sep 2014	13F
WALL STREET ASSOCIATES	13F	Company	0.05%	57,330	$1,108,000	—	30 Sep 2014	13F
COLUMBUS CIRCLE INVESTORS	13F	Company	0.05%	55,741	$1,077,000	—	30 Sep 2014	13F
TCW GROUP INC	13F	Company	0.05%	55,722	$1,077,000	—	30 Sep 2014	13F
Standard Investments LLC	13F	Company	0.05%	47,846	$925,000	—	30 Sep 2014	13F
BAMCO INC /NY/	13F	Company	0.04%	43,000	$831,000	—	30 Sep 2014	13F
PDT Partners, LLC	13F	Company	0.04%	42,070	$813,000	—	30 Sep 2014	13F
Robert W. Baird & Co. Inc	13F	Company	0.03%	36,078	$697,000	—	30 Sep 2014	13F
Alyeska Investment Group, L.P.	13F	Company	0.03%	32,360	$626,000	—	30 Sep 2014	13F
TIAA CREF INVESTMENT MANAGEMENT LLC	13F	Company	0.03%	28,872	$558,000	—	30 Sep 2014	13F
CITADEL ADVISORS LLC	13F	Company	0.03%	27,554	$533,000	—	30 Sep 2014	13F
BlackRock Investment Management, LLC	13F	Company	0.03%	26,314	$509,000	—	30 Sep 2014	13F
State of New Jersey Common Pension Fund D	13F	Company	0.02%	26,000	$503,000	—	30 Sep 2014	13F
SECOR Capital Advisors, LP	13F	Company	0.02%	22,175	$429,000	—	30 Sep 2014	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.02%	19,247	$373,000	—	30 Sep 2014	13F
Nationwide Fund Advisors	13F	Company	0.02%	19,150	$370,000	—	30 Sep 2014	13F

Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q4 2014

As of 31 Dec 2014, Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by 68 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 19,758,262 shares. The largest 10 holders included Essex Woodlands Health Ventures, Inc., NQ HCIF GP, Ltd., FRANKLIN RESOURCES INC, Polar Capital LLP, Bank of New York Mellon Corp, Visium Asset Management, LP, Arrowpoint Asset Management, LLC, JPMORGAN CHASE & CO, ALLIANCEBERNSTEIN L.P., and BlackRock Fund Advisors. This page lists 68 institutional shareholders reporting positions in this security for the Q4 2014 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2014 vs Q3 2014 Across Filers

Q3 2014 holders

Q4 2014 holders

Holder diff

-12

Investor	Q3 2014 Shares	Q4 2014 Shares	Share Diff	Share Chg %	Q3 2014 Value $	Q4 2014 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.